The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
Abstract
Purpose: The decision about prophylactic oophorectomy is difficult for many premenopausal women with BRCA1/2 mutations because of concerns and controversy about the use of hormone replacement therapy (HRT) after oophorectomy. Patients and Methods: A Markov decision analytic model used the most current epidemiologic data to assess the expected outcomes of prophylactic oophorectomy with or without HRT (to age 50 years or for life) in cohorts of women with BRCA1/2 mutations. Sensitivity analyses were conducted to assess the impact of alternative assumptions about effects of HRT, effects of prophylactic oophorectomy, and risks of cancer associated with BRCA1/2 mutations. Results: In our model, prophylactic oophorectomy lengthened life expectancy in women with BRCA1/2 mutations, irrespective of whether HRT was used after oophorectomy. This gain ranged from 3.34 to 4.65 years, depending on age at oophorectomy. Use of HRT after oophorectomy was associated with relatively small changes in life expectancy (+0.17 to −0.34 years) when HRT was stopped at age 50, but larger decrements in life expectancy if HRT was continued for life (−0.79 to −1.09 years). HRT was associated with a gain in life expectancy of between 0.39 and 0.79 years for mutation carriers undergoing both prophylactic mastectomy and oophorectomy. Conclusion: On the basis of the results of this decision analysis, we recommend that women with BRCA1/2 mutations undergo prophylactic oophorectomy after completion of childbearing, decide about short-term HRT after oophorectomy based largely on quality-of-life issues rather than life expectancy, and, if using HRT, consider discontinuing treatment at the time of expected natural menopause, approximately age 50 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973 · cited 1×
“0 [43]”
The Markov process in medical prognosis
Beck, J. R., & Pauker, S. G. (1983) · Medical Decision Making · doi:10.1177/0272989x8300300403 · Cited by 957 · cited 2×
“0 (Treeage Software, Williamstown, MA) to represent the impact of prophylactic oophorectomy and HRT on five major diseases: breast cancer, ovarian cancer, CHD, osteoporosis, and venous thrombosis [12].”
BackgroundMethodBurke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955 · cited 1×
“However, increased frequency of screening, potentially higher compliance, and increased use of alternative modalities may improve effectiveness [55].”
BackgroundEffects of estrogen plus progestin on health-related quality of life
Hays, J., Ockene, J. K., Brunner, R. L., Kotchen, J. M., Manson, J. E., Patterson, R. E., Aragaki, A. K., Shumaker, S. A., Brzyski, R. G., LaCroix, A. Z., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030311 · Cited by 686
Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios
Kinosian, B., Glick, H., & Garland, G. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00002 · Cited by 519 · cited 1×
“[23]”
Patient-specific decisions about hormone replacement therapy in postmenopausal women
Col, N. F. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540380054031 · Cited by 229
Cited by
ESHRE Guideline: management of women with premature ovarian insufficiency
(2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,555
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., Shoupe, D., Berek, J. S., Hankinson, S., & Manson, J. E. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181a11c64 · Cited by 640
Survival patterns after oophorectomy in premenopausal women: a population-based cohort study
Rocca, W. A., Grossardt, B. R., de Andrade, M., Malkasian, G. D., & Melton, L. J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70869-5 · Cited by 547
Increased cardiovascular mortality after early bilateral oophorectomy
Rivera, C. M., Grossardt, B. R., Rhodes, D. J., Brown, R. D., Roger, V. L., Melton, L. J., & Rocca, W. A. (2009) · Menopause · doi:10.1097/gme.0b013e31818888f7 · Cited by 481
Rebbeck, T. R., Friebel, T., Wagner, T., Lynch, H. T., Garber, J. E., Daly, M. B., Isaacs, C., Olopade, O. I., Neuhausen, S. L., van ′t Veer, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.8151 · Cited by 411
Self-citationRocca, W. A., Grossardt, B. R., & Shuster, L. T. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.031 · Cited by 283
“Natural menopause is defined as cessation of menses for 12 continuous months or more in the absence of a medical or surgical cause (Utian, 2001), and the median age at natural menopause is approximately 51 years (Armstrong et al., 2004;Shuster et al., 2010).”
BackgroundOvarian Conservation at the Time of Hysterectomy for Benign Disease
Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., & Berek, J. S. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000167394.38215.56 · Cited by 264
Effect of Bilateral Oophorectomy on Women's Long-Term Health
Parker, W. H., Jacoby, V., Shoupe, D., & Rocca, W. (2009) · Women's Health · doi:10.2217/whe.09.42 · Cited by 161
HRT for women with premature ovarian insufficiency: a comprehensive review
Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N. (2017) · Human Reproduction Open · doi:10.1093/hropen/hox007 · Cited by 141
Impact of risk-reducing salpingo-oophorectomy in premenopausal women
Vermeulen, R. F. M., Beurden, M. V., Korse, C. M., & Kenter, G. G. (2017) · Climacteric · doi:10.1080/13697137.2017.1285879 · Cited by 62
Risk‐Reduction Surgery Decisions in High‐Risk Women Seen for Genetic Counseling
Ray, J. A., Loescher, L. J., & Brewer, M. (2005) · Journal of Genetic Counseling · doi:10.1007/s10897-005-5833-5 · Cited by 53
D'Alonzo, M., Piva, E., Pecchio, S., Liberale, V., Modaffari, P., Ponzone, R., & Biglia, N. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.015 · Cited by 41
Premature menopause and risk of neurological disease: Basic mechanisms and clinical implications
Scott, E. L., Zhang, Q.-G., Vadlamudi, R. K., & Brann, D. W. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.01.013 · Cited by 36
Lobb, E., & Meiser, B. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16393-9 · Cited by 23
AlHilli, M. M., & Al-Hilli, Z. (2019) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2018.09.767 · Cited by 15
Metadata
- Authors
- Armstrong, K., Schwartz, J. S., Randall, T., Rubin, S. C., & Weber, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-03-15
- Volume
- 22
- Issue
- 6
- Pages
- 1045-1054
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106616822
- Cited by
- 162
- References
- 9
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.